Fondaparinux
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Fondaparinux and local guidelines before prescribing.
Factor Xa inhibitor
Mechanism
Synthetic pentasaccharide factor Xa inhibitor.
Uses
VTE prophylaxis and treatment, ACS, heparin-induced thrombocytopenia (alternative).
Dosing
- Fondaparinux 2.5 mg SC daily unless high bleeding risk or angiography is planned within 24 hours. Avoid if eGFR is below 20 - use unfractionated heparin.
Cardiology: Cardiology Emergencies - Fondaparinux NSTE-ACS | 2.5 mg SC daily. Avoid if eGFR below 20.
Cardiology: Cardiology Emergencies - Fondaparinux 2.5 mg SC daily for patients without high bleeding risk who are not having immediate angiography (NICE). Use unfractionated heparin instead if creatinine is above 265 µmol/L.
Cardiology: Ischaemic Heart Disease (ACS) - Fondaparinux | 2.5 mg SC daily up to 8 days. Avoid if CrCl <20 mL/min. Extra UFH needed during PCI.
Cardiology: Ischaemic Heart Disease (ACS)
6 more dose entries from the chapters
- VTE prophylaxis in hospital (NICE NG89) - assess every adult on admission for VTE and bleeding risk; LMWH (e.g. enoxaparin 40 mg daily, adjusted for weight and kidney function) or fondaparinux; mechanical options (intermittent pneumatic compression - not anti-embolism stockings in acute stroke ); reassess regularly.
Haematology: Anatomy Physiology and Pharmacology - Superficial vein thrombosis - NSAIDs and compression. Fondaparinux 2.5 mg daily for 45 days if 5 cm or longer, or near the saphenofemoral junction (within 3 cm - then scan, as it may need full treatment).
Haematology: Haemostasis and Thrombosis - LMWH (e.g. enoxaparin 40 mg once daily ; 20 mg if creatinine clearance is under 30), or fondaparinux, for at least 7 days if risk outweighs bleeding risk.
Haematology: Haemostasis and Thrombosis - Fondaparinux 2.5 mg daily | Superficial vein thrombosis (45 days); HIT alternative.
Haematology: Haemostasis and Thrombosis - Treatment - aspirin 300 mg, fondaparinux (unless angiography soon), second antiplatelet per protocol, beta-blocker, GTN; risk-stratify with GRACE - angiography within 72 hours for intermediate or higher risk (see the Cardiology chapters).
Acute Medicine: Acute chest pain, breathlessness, collapse and blood gases - Pharmacological prophylaxis - LMWH (e.g. enoxaparin 40 mg daily - adjust for weight and kidney function) or fondaparinux, for at least 7 days if VTE risk outweighs bleeding risk; unfractionated heparin in severe kidney impairment (eGFR under 15–30).
Acute Medicine: The acute medical take
Side effects
Bleeding, anaemia, injection-site reactions.
Interactions
Anticoagulants and antiplatelets.
Contraindications and cautions
Active bleeding, CrCl below 20, endocarditis
Monitoring
Renal function, Hb
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Avoid if CrCl below 20
Overdose and reversal
Andexanet or prothrombin complex concentrate
Special advice
Contraindicated if CrCl below 20; no HIT risk.
More from the textbook: uses, cautions and other points
- Fondaparinux - synthetic Xa inhibitor (via antithrombin); used in NSTEMI in some protocols.
Cardiology: Anatomy Physiology and Pharmacology - Pharmacological prophylaxis — LMWH (or fondaparinux; DOACs after hip and knee replacement); adjust for renal function and weight; unfractionated heparin in severe renal impairment.
Cardiology: Venous Thromboembolism and Pulmonary Vascular Disease - Fondaparinux - synthetic factor Xa inhibitor (via antithrombin); once-daily SC; VTE prophylaxis and treatment, acute coronary syndrome; kidney excretion (avoid in severe CKD); doesn't cause HIT; not reversed by protamine.
Haematology: Anatomy Physiology and Pharmacology - Fondaparinux | Factor Xa via antithrombin; no HIT; avoid in severe CKD.
Haematology: Anatomy Physiology and Pharmacology - Assess with the 4Ts score; test for HIT antibodies; stop all heparin and start a non-heparin anticoagulant (argatroban, danaparoid, fondaparinux); don't give platelets.
Cardiology: Anatomy Physiology and Pharmacology - Stop all heparin (including flushes); start a non-heparin anticoagulant (argatroban or fondaparinux, per haematology).
Cardiology: Anatomy Physiology and Pharmacology - During PCI: Extra unfractionated heparin must be given, because fondaparinux alone allows clots to form on catheters.
Cardiology: Ischaemic Heart Disease (ACS) - Stop all heparin (including line flushes and heparin-coated catheters); start a non-heparin anticoagulant (argatroban, danaparoid, fondaparinux or a DOAC - specialist advice).
Haematology: Anatomy Physiology and Pharmacology
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (3 mentions)
- Cardiology: Cardiology Emergencies (2 mentions)
- Cardiology: Ischaemic Heart Disease (ACS) (3 mentions)
- Cardiology: Venous Thromboembolism and Pulmonary Vascular Disease (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (5 mentions)
- Haematology: Emergencies (1 mention)
- Haematology: Haemostasis and Thrombosis (4 mentions)
- Surgery: Vascular surgery (1 mention)
- Clinical pharmacology and prescribing: High-risk drugs, therapeutic drug monitoring, IV fluids and antimicrobial prescribing (1 mention)
- Acute Medicine: Acute chest pain, breathlessness, collapse and blood gases (1 mention)
- Acute Medicine: The acute medical take (2 mentions)
- Integrated cardiology chapter (3 mentions)